GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
L

Lepu Biopharma Co 2157.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

2.97

+3.13%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Lepu Biopharma Co

Its shares trade on HKEX under the ticker 2157.HK. It has been listed since 23 February 2022. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.06bn and net income of CN¥296.4m. At that date it held total assets of CN¥3.61bn and shareholders' equity of CN¥1.61bn.

Lepu Biopharma Co., Ltd. is an innovation-driven biopharmaceutical company, which focuses on oncology therapeutics and endeavor to continuously develop a market differentiating pipeline by combining in-house research and development and strategic collaborations, strengthen in-house manufacturing and commercialize its pipeline products in China through dedicated sales and marketing forces and internationally via partnerships. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2022-02-23. The firm mainly develops product lines of tumor candidate drugs, including antibody drug conjugate (ADC), oncolytic virus drug products and immunotherapy at clinical and pre-clinical stages. The Company’s major pipeline assets consist of MRG003, MRG002, HX008 and LP002, and three key clinical-stage drug candidates. The firm's products are sold at home and abroad.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
23 Feb 2022
Employees
436

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Innovation-driven biopharmaceutical company with oncology focus in China.
  • Develops antibody drug conjugate (ADC) and immunotherapy products in clinical stages.
  • MRG003, MRG002, HX008, and LP002 are key pipeline assets.

Weaknesses

  • 436 employees limit scale of operations and R&D capacity.
  • IPO on 23 February 2022 indicates recent market entry.
  • Reliance on strategic collaborations for pipeline development.

Opportunities

  • Expanding international partnerships for global market access.
  • Growing demand for oncology therapeutics in China and abroad.
  • Clinical-stage drug candidates present commercialization potential.

Threats

  • Competition in oncology therapeutics sector remains intense.
  • Regulatory challenges in international markets may delay approvals.
  • Economic downturns could impact investment in biotech R&D.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.